Movement Alert|Spyre Therapeutics Rises 11.41% in Regular Trading, Trading at $104.42

Market Focus
07/15

On July 15, Spyre Therapeutics rose 11.41% in regular trading, trading at $104.42 USD/share, with Turnover of $74.60 million.

Within the Biotechnology sector where Spyre Therapeutics belongs, individual stock performance was mixed. Among individual stocks, Nextcure Inc. up 226.15%, Biogen down 8.48%, AbbVie down 1.26%, Shuttle Pharmaceuticals Inc up 30.07%, Gilead Sciences down 0.54%.

Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation inflammatory bowel disease therapeutics through long-acting antibodies and antibody combinations targeting α4β7, TL1A, and IL-23. The company reported Q4 net loss of $0.70 per share and holds $757 million in cash with runway into Q2 2028.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10